Update on Acquisition of Oncogeni and Placing

RNS Number : 8587P

Roquefort Therapeutics PLC

23 June 2022

 

23 June 2022

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

Update on Acquisition of Oncogeni Limited and Placing

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on early-stage opportunities in the biotechnology sector, is pleased to announce that it has published a corporate presentation with respect to the proposed acquisition of Oncogeni Limited and the proposed Placing, as announced by the Company on 22 June 2022.  A copy of the presentation is available on the Company's website at https://www.roquefortplc.com/category/presentations/

The Company looks forward to providing further updates in relation to the acquisition of Oncogeni Limited and the Placing as and when appropriate.

 

Enquiries:

Roquefort Therapeutics plc Stephen West (Chairman) [phone] Buchanan (Public Relations) Ben Romney / Jamie Hooper / George Beale Optiva Securities Limited (Broker) [phone] Christian Dennis [phone]

For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on Twitter.

LEI: ‎254900P4SISIWOR9RH34

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company developing products through the pre-clinical phase prior to partnering or selling to big pharma. The Company is a pre-clinical biotech company focused on developing first in class Midkine targeting drugs for the treatment of cancer.

Through extensive research resulting in validation through publication in over 1,000 scientific journals, Roquefort Therapeutics has identified the potential to exploit the broad therapeutic potential of Midkine for a number of clinical indications of unmet needs. Roquefort Therapeutics holds an exclusive licence to the largest global IP portfolio on Midkine. The Midkine blocking drug development markets have significant global market potential (in the multi-billion dollars). Roquefort Therapeutic's pre-clinical program is currently underway with an initial focus on cancer.

 

END

 

 

ACQELLFLLQLZBBX